{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:51:45Z","timestamp":1791359505566,"version":"4.3.1"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021079","name":"Lizanell and Colbert Coldwell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021079","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>The ubiquitin\u2013proteasome system (UPS) is the primary intracellular pathway for maintaining protein homeostasis through the selective degradation of ubiquitinated proteins. Central to this process is the 26S proteasome, which orchestrates the turnover of regulatory and misfolded proteins and thereby controls critical cellular functions, including cell-cycle progression, apoptosis, DNA repair, signal transduction, and stress response pathways. Dysregulation of proteasome function contributes to many hallmarks of cancer, leading to malignant transformation, disease progression, and therapeutic resistance, making the proteasome an attractive target for anticancer therapy. Clinically approved proteasome inhibitors, including bortezomib, carfilzomib, and ixazomib, have significantly improved outcomes in multiple myeloma and other hematologic malignancies by targeting the catalytic activity of the 20S core particle. However, their long-term clinical benefit is limited by intrinsic and acquired resistance and treatment-related toxicities. Recent studies have identified the 19S regulatory particle as a mechanistically distinct and therapeutically promising target. Unlike the proteolytic 20S core, the 19S complex controls substrate recognition, deubiquitination, unfolding, and translocation into the proteolytic chamber. Beyond its role in protein degradation, the 19S regulatory particle participates in transcriptional regulation, chromatin remodeling, and DNA damage responses. Several 19S subunits, particularly members of the PSMD and PSMC families, are overexpressed in hematologic and solid malignancies and are associated with poor clinical outcomes. Genetic and pharmacologic targeting of 19S ATPases and deubiquitinating enzymes induces proteotoxic stress, overcomes resistance to conventional proteasome inhibitors, and suppresses tumor growth in preclinical models. In this review, we discuss the biological functions of the 19S regulatory particle, its role in cancer pathogenesis, and emerging therapeutic strategies targeting 19S-associated proteins to improve outcomes in hematologic malignancies.<\/jats:p>","DOI":"10.3389\/fcell.2026.1918833","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:11:45Z","timestamp":1791357105000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The 19S proteasome as a therapeutic target in hematologic malignancies"],"prefix":"10.3389","volume":"14","author":[{"given":"Idaly M.","family":"Olivas","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, University of Texas at El Paso","place":["El Paso, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra A.","family":"Gonzalez-Henry","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Texas at El Paso","place":["El Paso, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeedeh","family":"Darvishi","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Texas at El Paso","place":["El Paso, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn M.","family":"Esparza","sequence":"additional","affiliation":[{"name":"Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso","place":["El Paso, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Eiring","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Texas at El Paso","place":["El Paso, TX, United States"]},{"name":"Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso","place":["El Paso, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ccr.2013.11.001","article-title":"A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13\/ADRM1 as a therapy for cancer","volume":"24","author":"Anchoori","year":"2013","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41580-024-00778-0","article-title":"Mechanisms and regulation of substrate degradation by the 26S proteasome","volume":"26","author":"Arkinson","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/cancers10100351","article-title":"Combined effect of bortezomib and menadione sodium bisulfite on proteasomes of tumor cells: the dramatic decrease of bortezomib toxicity in a preclinical trial","volume":"10","author":"Astakhova","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","article-title":"Structure and function of the 26S proteasome","volume":"87","author":"Bard","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbamcr.2013.02.028","article-title":"The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer","volume":"1843","author":"Bassermann","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"B8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1038\/s41388-021-01732-6","article-title":"Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B","volume":"40","author":"Bencomo-Alvarez","year":"2021","journal-title":"Oncogene"},{"key":"B10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41419-022-04508-2","article-title":"Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer","volume":"13","author":"Bi","year":"2022","journal-title":"Cell Death Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/life16030428","article-title":"Autophagy and lipid metabolism as a therapeutic target for overcoming drug resistance in acute myeloid leukemia","volume":"16","author":"Bolandi","year":"2026","journal-title":"Life (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3109\/10428194.2013.806799","article-title":"Bortezomib inhibits proteasomal degradation of I\u03baB\u03b1 and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma","volume":"55","author":"Bu","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"B13","doi-asserted-by":"publisher","first-page":"12991","DOI":"10.1073\/pnas.1614614113","article-title":"Structural basis for dynamic regulation of the human 26S proteasome","volume":"113","author":"Chen","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B14","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann. Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1531797","DOI":"10.3389\/fcell.2024.1531797","article-title":"Mechanisms of ubiquitin-independent proteasomal degradation and their roles in age-related neurodegenerative disease","volume":"12","author":"Church","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/nm.2536","article-title":"Inhibition of proteasome deubiquitinating activity as a new cancer therapy","volume":"17","author":"D'Arcy","year":"2011","journal-title":"Nat. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2014.11.002","article-title":"Deubiquitinase inhibition as a cancer therapeutic strategy","volume":"147","author":"D'Arcy","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s0305-7372(03)00077-x","article-title":"The tumor microenvironment: focus on myeloma","volume":"29","author":"Dalton","year":"2003","journal-title":"Cancer Treat. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/ejh.12784","article-title":"Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma","volume":"98","author":"Delforoush","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.3390\/cancers12071898","article-title":"The ubiquitin proteasome system in hematological malignancies: new insight into its functional role and therapeutic options","volume":"12","author":"Di Costanzo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1038\/s41401-023-01136-0","article-title":"Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells","volume":"44","author":"Ding","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41586-018-0736-4","article-title":"Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome","volume":"565","author":"Dong","year":"2019","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41375-020-0865-2","article-title":"Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13","volume":"35","author":"Du","year":"2021","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1182\/blood.2025029358","article-title":"Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma","volume":"147","author":"Du","year":"2026","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1017\/S1462399411002031","article-title":"Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases","volume":"13","author":"Edelmann","year":"2011","journal-title":"Expert Rev. Mol. Med."},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1101\/2025.01.31.634950","volume-title":"Proteasome Inhibition Enhances lysosome-mediated Targeted Protein Degradation","author":"Elshazly","year":"2025"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-33198-0_3","volume-title":"The Choice of first-line Chronic Myelogenous Leukemia Treatment","author":"Fava","year":"2016"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.3390\/cancers15082312","article-title":"Targeting FLT3 mutation in acute myeloid leukemia: current strategies and future directions","volume":"15","author":"Fedorov","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.3390\/jcm10081783","article-title":"Role of proteasomes in inflammation","volume":"10","author":"Goetzke","year":"2021","journal-title":"J. Clin. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1158\/1078-0432.CCR-12-2754","article-title":"The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-\u03baB response in chronic lymphocytic leukemia cells","volume":"19","author":"Gupta","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3390\/cancers15020532","article-title":"Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma","volume":"15","author":"Haertle","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2026.02.012","article-title":"Quinoxaline-based UCHL5 inhibitor as a next-generation proteasome-targeting anticancer agent beyond 20S inhibition","author":"Han","year":"2026","journal-title":"J. Adv. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"657917","DOI":"10.3389\/fcell.2021.657917","article-title":"PSMC5 promotes proliferation and metastasis of colorectal cancer by activating epithelial-mesenchymal transition signaling and modulating immune infiltrating cells","volume":"9","author":"He","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1016\/j.molcel.2023.10.019","article-title":"The proteasome component PSMD14 drives myelomagenesis through a histone deubiquitinase activity","volume":"83","author":"He","year":"2023","journal-title":"Mol. Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the children's oncology group","volume":"186","author":"Horton","year":"2019","journal-title":"Br. J. Haematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/pbc.21214","article-title":"Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program","volume":"50","author":"Houghton","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"10883","DOI":"10.1038\/s41598-021-90451-9","article-title":"Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein","volume":"11","author":"Jenkins","year":"2021","journal-title":"Sci. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1038\/s12276-023-01087-w","article-title":"Targeting E3 ubiquitin ligases and their adaptors as a therapeutic strategy for metabolic diseases","volume":"55","author":"Jeong","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1017866","DOI":"10.3389\/fgene.2022.1017866","article-title":"Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma","volume":"13","author":"Jia","year":"2022","journal-title":"Front. Genet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.4049\/jimmunol.1201183","article-title":"Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation","volume":"189","author":"Kalim","year":"2012","journal-title":"J. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-3-030-40204-4_10","article-title":"Lessons learned from proteasome inhibitors, the paradigm for targeting protein homeostasis in cancer","volume":"1243","author":"Kambhampati","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"17970","DOI":"10.18632\/aging.203345","article-title":"Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer","volume":"13","author":"Kao","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.celrep.2018.06.058","article-title":"Dual function of USP14 deubiquitinase in cellular proteasomal activity and autophagic flux","volume":"24","author":"Kim","year":"2018","journal-title":"Cell Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s12272-023-01455-0","article-title":"Ubiquitin-proteasome system as a target for anticancer treatment-an update","volume":"46","author":"Kim","year":"2023","journal-title":"Arch. Pharm. Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-biophys-083012-130417","article-title":"Structural biology of the proteasome","volume":"42","author":"Kish-Trier","year":"2013","journal-title":"Annu. Rev. Biophys."},{"key":"B50","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00262-018-2151-y","article-title":"The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma","volume":"67","author":"Kropp","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-15-2522","article-title":"Carfilzomib triggers cell death in chronic lymphocytic leukemia by inducing proapoptotic and endoplasmic reticulum stress responses","volume":"22","author":"Lamothe","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature10774","article-title":"Complete subunit architecture of the proteasome regulatory particle","volume":"482","author":"Lander","year":"2012","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","first-page":"14586","DOI":"10.3390\/ijms232314586","article-title":"19S proteasome subunits as oncogenes and prognostic biomarkers in FLT3-Mutated acute myeloid leukemia (AML)","volume":"23","author":"Lara","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1073\/pnas.1120559109","article-title":"Molecular architecture of the 26S proteasome holocomplex determined by an integrative approach","volume":"109","author":"Lasker","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B55","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41418-020-00667-x","article-title":"Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective","volume":"28","author":"Le Guerrou\u00e9","year":"2021","journal-title":"Cell Death Differ."},{"key":"B56","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40364-021-00320-w","article-title":"Deubiquitinases in hematological malignancies","volume":"9","author":"Lei","year":"2021","journal-title":"Biomark. Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nchembio.2326","article-title":"Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11","volume":"13","author":"Li","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1186\/s12885-023-11017-8","article-title":"PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation","volume":"23","author":"Li","year":"2023","journal-title":"BMC Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"101150","DOI":"10.1016\/j.gendis.2023.101150","article-title":"Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"11","author":"Li","year":"2024","journal-title":"Genes Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12935-023-03164-6","article-title":"The function and mechanism of PSMD14 in promoting progression and resistance to anlotinib in osteosarcoma","volume":"23","author":"Liu","year":"2023","journal-title":"Cancer Cell Int."},{"key":"B62","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2050-7771-1-13","article-title":"The resistance mechanisms of proteasome inhibitor bortezomib","volume":"1","author":"Lu","year":"2013","journal-title":"Biomark. Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"157496","DOI":"10.1155\/2012\/157496","article-title":"Bone marrow microenvironment in multiple myeloma progression","volume":"2012","author":"Manier","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fmolb.2019.00040","article-title":"Dynamic regulation of the 26S proteasome: from synthesis to degradation","volume":"6","author":"Marshall","year":"2019","journal-title":"Front. Mol. Biosci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"E494","DOI":"10.1002\/ijc.26468","article-title":"Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer","volume":"131","author":"McCawley","year":"2012","journal-title":"Int. J. Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","article-title":"Mechanisms of proteasome inhibitor action and resistance in cancer","volume":"11","author":"McConkey","year":"2008","journal-title":"Drug Resist Updat"},{"key":"B67","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CMAR.S105163","article-title":"Update on the optimal use of bortezomib in the treatment of multiple myeloma","volume":"9","author":"Mohan","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.3390\/ijms22126213","article-title":"Small-molecule inhibitors targeting proteasome-associated deubiquitinases","volume":"22","author":"Moon","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"100663","DOI":"10.1016\/j.drup.2019.100663","article-title":"Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance","volume":"48","author":"Narayanan","year":"2020","journal-title":"Drug Resist Updat"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1443399","DOI":"10.3389\/fonc.2024.1443399","article-title":"Racial\/Ethnic differences in the clinical presentation and survival of breast cancer by subtype","volume":"14","author":"Nhim","year":"2024","journal-title":"Front. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3324\/haematol.2013.092411","article-title":"Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors","volume":"98","author":"Niewerth","year":"2013","journal-title":"Haematologica"},{"key":"B72","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-016-0312-z","article-title":"Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy","volume":"9","author":"Niewerth","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/cells10123464","article-title":"The role of chaperone-mediated autophagy in bortezomib resistant multiple myeloma","volume":"10","author":"Nikesitch","year":"2021","journal-title":"Cells"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12964-023-01433-5","article-title":"Interplay between proteasome inhibitors and NF-\u03baB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors","volume":"22","author":"Pakjoo","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"B76","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.tips.2023.05.006","article-title":"Overcoming proteasome inhibitor resistance in the immunotherapy era","volume":"44","author":"Patino-Escobar","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"113256","DOI":"10.1016\/j.jbc.2026.113256","article-title":"Structural mechanism of 26S proteasome regulation and its pharmacological modulation","volume":"302","author":"Pei","year":"2026","journal-title":"J. Biol. Chem."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1351565","DOI":"10.3389\/fphar.2024.1351565","article-title":"Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells","volume":"15","author":"Pelon","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3390\/ijms21020613","article-title":"Bone marrow stromal cells-induced drug resistance in multiple myeloma","volume":"21","author":"Ria","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B80","doi-asserted-by":"publisher","first-page":"100016","DOI":"10.1074\/mcp.R120.002190","article-title":"Proteome turnover in the spotlight: approaches, applications, and perspectives","volume":"20","author":"Ross","year":"2021","journal-title":"Mol. Cell Proteomics"},{"key":"B81","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41580-018-0040-z","article-title":"Regulation of proteasome assembly and activity in health and disease","volume":"19","author":"Rousseau","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/s1097-2765(01)80001-0","article-title":"The 19S regulatory complex of the proteasome functions independently of proteolysis in nucleotide excision repair","volume":"3","author":"Russell","year":"1999","journal-title":"Mol. Cell"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1111\/febs.12814","article-title":"A novel role for the proteasomal chaperone PSMD9 and hnRNPA1 in enhancing I\u03baB\u03b1 degradation and NF-\u03baB activation - functional relevance of predicted PDZ domain-motif interaction","volume":"281","author":"Sahu","year":"2014","journal-title":"Febs J."},{"key":"B84","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1021\/acs.biochem.2c00245","article-title":"Molecular glues: the adhesive connecting targeted protein degradation to the clinic","volume":"62","author":"Sasso","year":"2023","journal-title":"Biochemistry"},{"key":"B85","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2010.07.036","article-title":"Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress","volume":"142","author":"Seifert","year":"2010","journal-title":"Cell"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1158\/1541-7786.MCR-15-0135","article-title":"When cancer fights back: multiple myeloma, proteasome inhibition, and the heat-shock response","volume":"13","author":"Shah","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00432-024-05716-3","article-title":"Gastrointestinal toxicities of proteasome inhibitor therapy","volume":"150","author":"Shah","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"802832","DOI":"10.3389\/fonc.2021.802832","article-title":"The role of proteasome inhibitors in treating acute lymphoblastic leukaemia","volume":"11","author":"Sin","year":"2021","journal-title":"Front. Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/leu.2016.97","article-title":"Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma","volume":"30","author":"Song","year":"2016","journal-title":"Leukemia"},{"key":"B90","doi-asserted-by":"publisher","first-page":"5631","DOI":"10.1038\/onc.2017.172","article-title":"Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"36","author":"Song","year":"2017","journal-title":"Oncogene"},{"key":"B91","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41416-022-01829-z","article-title":"POH1\/Rpn11\/PSMD14: a journey from basic research in fission yeast to a prognostic marker and a druggable target in cancer cells","volume":"127","author":"Spataro","year":"2022","journal-title":"Br. J. Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/onc.2013.60","article-title":"DNA damage emergency: cellular garbage disposal to the rescue?","volume":"33","author":"Stone","year":"2014","journal-title":"Oncogene"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3390\/biom13091326","article-title":"Structure, function, and allosteric regulation of the 20S proteasome by the 11S\/PA28 family of proteasome activators","volume":"13","author":"Thomas","year":"2023","journal-title":"Biomolecules"},{"key":"B94","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","article-title":"A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance","volume":"123","author":"Tian","year":"2014","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3390\/cells10123587","article-title":"The functional and mechanistic roles of immunoproteasome subunits in cancer","volume":"10","author":"Tripathi","year":"2021","journal-title":"Cells"},{"key":"B96","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1073\/pnas.1619067114","article-title":"Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers","volume":"114","author":"Tsvetkov","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/cells10071577","article-title":"Immunoproteasome function in normal and malignant hematopoiesis","volume":"10","author":"Tubio-Santamaria","year":"2021","journal-title":"Cells"},{"key":"B98","doi-asserted-by":"publisher","first-page":"107579","DOI":"10.1016\/j.pharmthera.2020.107579","article-title":"The proteasome as a druggable target with multiple therapeutic potentialities: cutting and non-cutting edges","volume":"213","author":"Tundo","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1209425","DOI":"10.3389\/fmed.2023.1209425","article-title":"The prognostic value of 19S ATPase proteasome subunits in acute myeloid leukemia and other forms of cancer","volume":"10","author":"Tychhon","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"B100","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1126\/science.1075898","article-title":"Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome","volume":"298","author":"Verma","year":"2002","journal-title":"Science"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1010428317692248","DOI":"10.1177\/1010428317692248","article-title":"Proteasome expression and activity in cancer and cancer stem cells","volume":"39","author":"Voutsadakis","year":"2017","journal-title":"Tumour Biol."},{"key":"B102","first-page":"2103","article-title":"PSMB5 plays a dual role in cancer development and immunosuppression","volume":"7","author":"Wang","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"107526","DOI":"10.1016\/j.pharmthera.2020.107526","article-title":"Exploring the proteasome system: a novel concept of proteasome inhibition and regulation","volume":"211","author":"Wang","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1002\/ctd2.242","article-title":"Targeting deubiquitinases for cancer therapy","volume":"3","author":"Xue","year":"2023","journal-title":"Clin. Transl. Discov."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/14740338.2024.2393275","article-title":"Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system","volume":"24","author":"Yu","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"B106","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3390\/cancers12040902","article-title":"Drug development targeting the ubiquitin\u2013proteasome system (UPS) for the treatment of human cancers","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers"},{"key":"B107","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.7150\/ijbs.130350","article-title":"PSMC5 orchestrates an immunosuppressive niche and metastasis in colorectal cancer via SMURF1-Mediated K11-Linked ubiquitination of METTL14","volume":"22","author":"Zhang","year":"2026","journal-title":"Int. J. Biol. Sci."},{"key":"B108","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.1038\/onc.2016.114","article-title":"A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy","volume":"35","author":"Zhao","year":"2016","journal-title":"Oncogene"},{"key":"B109","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1918833\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:11:47Z","timestamp":1791357107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1918833\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":107,"alternative-id":["10.3389\/fcell.2026.1918833"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1918833","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1918833"}}